Meanwhile, studies found that the use of long-acting insulin analogs (insulin glargine and detemir) did not increase risk of CRC for patients with T2DM [103, 104], but at the same times, one cohort study found no evidence of significant differences in risk for ten cancers including CRC for insulin glargine or insulin detemir use compared with human insulin [105]. The gene discussed is INS; the disease is type 2 diabetes mellitus.